The European Union's pharmaceutical reforms must maintain the current patent protection baseline, says David Kolář, executive ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

A new study reveals that more than half of cancer drugs approved by the FDA under accelerated pathways are not authorized in ...

InflaRx (IFRX) has released an update. InflaRx has received a positive opinion from the European Medicines Agency’s CHMP for GOHIBIC, a ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

As previously disclosed, the Common Stock was suspended from trading on Nasdaq as of October 3, 2024, pursuant to a final delisting notice sent to the Company by the Listing Qualifications Department ...

Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.

The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...